Rad5 Dysregulation Drives Hyperactive Recombination at Replication Forks Resulting in Cisplatin Sensitivity and Genome Instability Eric E

Total Page:16

File Type:pdf, Size:1020Kb

Rad5 Dysregulation Drives Hyperactive Recombination at Replication Forks Resulting in Cisplatin Sensitivity and Genome Instability Eric E 9144–9159 Nucleic Acids Research, 2019, Vol. 47, No. 17 Published online 27 July 2019 doi: 10.1093/nar/gkz631 Rad5 dysregulation drives hyperactive recombination at replication forks resulting in cisplatin sensitivity and genome instability Eric E. Bryant 1, Ivana Sunjevariˇ c´ 2, Luke Berchowitz2, Rodney Rothstein1,2,3 and Robert J.D. Reid 2,* 1Department of Biological Sciences, Columbia University, New York, NY 10027, USA, 2Department of Genetics & Development, Columbia University Irving Medical Center, New York, NY 10032, USA and 3Department of Systems Downloaded from https://academic.oup.com/nar/article/47/17/9144/5539889 by guest on 30 September 2021 Biology, Columbia University Irving Medical Center, New York, NY 10032, USA Received December 06, 2018; Revised June 14, 2019; Editorial Decision July 09, 2019; Accepted July 25, 2019 ABSTRACT cialized polymerases that can synthesize across damaged bases in a process called translesion synthesis, or through The postreplication repair gene, HLTF, is often am- bypassing lesions by continuing synthesis on undamaged plified and overexpressed in cancer. Here we model sister chromatid DNA in a process called template switch- HLTF dysregulation through the functionally con- ing (5). served Saccharomyces cerevisiae ortholog, RAD5. Translesion synthesis and template switching are some- Genetic interaction profiling and landscape enrich- times referred to as error-prone and error-free PRR re- ment analysis of RAD5 overexpression (RAD5OE)re- spectively owing to high rates of nucleotide misincorpo- veals requirements for genes involved in recombi- ration by translesion synthesis polymerases across from nation, crossover resolution, and DNA replication. damaged bases (6). However, template switching can cause While RAD5OE and rad5Δ both cause cisplatin sensi- errors through ectopic recombination, which can drive tivity and share many genetic interactions, RAD5OE loss or gain of information in repetitive DNA (7,8). Moreover, fork stalling and template switching result- specifically requires crossover resolving genes and ing in microhomology-mediated break-induced replica- drives recombination in a region of repetitive DNA. OE tion (BIR) is the proposed driving mechanism behind Remarkably, RAD5 induced recombination does disease-associated human genome rearrangements (9,10). not require other post-replication repair pathway In the absence of PRR, replication forks encountering a members, or the PCNA modification sites involved in DNA lesion are more prone to fork collapse which may regulation of this pathway. Instead, the RAD5OE phe- also result in a recombinogenic double-stranded DNA notype depends on a conserved domain necessary break and chromosomal rearrangements (11). Entry into for binding 3 DNA ends. Analysis of DNA replica- PRR is mediated by monoubiquitination of proliferat- tion intermediates supports a model in which dys- ing cell nuclear antigen (PCNA), performed in Saccha- regulated Rad5 causes aberrant template switching romyces cerevisiae by the Rad6–Rad18 complex (human / at replication forks. The direct effect of Rad5 on repli- UBE2A UBE2B-RAD18) (12). This initial modification of PCNA is thought to recruit translesion synthesis poly- cation forks in vivo, increased recombination, and merases to a stalled replication fork. Subsequent regula- cisplatin sensitivity predicts similar consequences tion of translesion synthesis/template switching pathway for dysregulated HLTF in cancer. choice is then thought to be mediated by the Mms2–Ubc13– Rad5 complex (human UBE2N-UBE2V2-HLTF), which INTRODUCTION can polyubiquitinate PCNA and perform replication fork remodeling to initiate template switching (13,14). Post-replication repair (PRR) is essential for damage Given the importance of PRR in responding to lesions tolerance during DNA replication. In the absence of caused by commonly used chemotherapeutic drugs, we this pathway, cells are acutely sensitive to intrastrand sought to determine whether this pathway incurs any fre- DNA crosslinking agents such as cisplatin––one of sev- quent genetic alterations in cancer genomes. In this study, eral platinum-based drugs used in an estimated 50% of all we perform an analysis of primary tumor samples from The chemotherapeutic regimens (1–4). PRR enables damage tol- Cancer Genome Atlas (TCGA), which reveals HLTF to be erance during replication either through recruitment of spe- *To whom correspondence should be addressed. Tel: +1 212 305 1734; Fax: +1 212 923 2090; Email: [email protected] C The Author(s) 2019. Published by Oxford University Press on behalf of Nucleic Acids Research. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] Nucleic Acids Research, 2019, Vol. 47, No. 17 9145 commonly amplified and overexpressed in esophageal, uter- We find that a Rad5 ATPase mutant, defective in translo- ine and several types of squamous cell carcinoma (15). This case activity (25), only partially relieves the consequences observation corroborates previous work showing overex- of RAD5OE, whereas a Rad5 HIRAN point mutation, iden- pression of HLTF at the RNA level in several cancer cell tified using a homology model of the HLTF ssDNA bind- lines and at the protein level in hypopharyngeal squamous ing HIRAN domain, nearly eliminates the RAD5OE pheno- cell carcinomas, as well as during early stages of carcino- type. By quantitative physical analysis of DNA replication genesis in a kidney tumor model (16–18). Paradoxically, intermediates, we demonstrate that RAD5OE promotes for- HLTF is also found to be frequently silenced by promoter mation of crossover products near an early firing replica- methylation in colorectal cancers (19), leading to conflict- tion origin. These products persist in the absence of Sgs1, a ing descriptions of HLTF as both a tumor suppressor and RecQ helicase involved in crossover resolution and depend driver. Ultimately, the role of variable HLTF expression on a functional Rad5 HIRAN domain. Our data support a in carcinogenesis remains unclear. Our goal is to under- model whereby RAD5OE bypasses PRR regulatory events to stand whether dysregulation of this gene could have func- promote aberrant template switching via HIRAN domain- Downloaded from https://academic.oup.com/nar/article/47/17/9144/5539889 by guest on 30 September 2021 tional consequences for cells, especially with respect to cel- mediated replication fork remodeling. The genomic ramifi- lular fitness, response to chemotherapy and maintenance of cations of RAD5OE presented here inform the mechanistic genome stability. consequences of HLTF misexpression and its potential ef- Human HLTF and its budding yeast homolog, Rad5, are fect on carcinogenesis, genome instability, and response to remarkably conserved in domain structure and biochemical platinum-based chemotherapy. function. HLTF and Rad5 share the eponymous HIP116, Rad5p N-terminal (HIRAN) domain –– an ancient region MATERIALS AND METHODS of amino acid sequence homology that has been shown to form an OB-fold structure which can bind to the 3 end of Strains and plasmids single-stranded DNA (ssDNA) (20–23). Downstream of the All strains are RAD5 derivatives of W303 (34), unless oth- / HIRAN domain, both HLTF and Rad5 have SWI2 SNF2 erwise stated. Library strains used in our genetic screens are helicase sequence homology interrupted by a RING finger derivatives of S288C (35). Strains and plasmids constructed domain (20,24). Biochemically, both proteins have adeno- for this study, or used in validation experiments, were ver- sine triphosphate (ATP)-dependent DNA translocase ac- ified by Sanger sequencing. All genotypes for strains and tivity, and are capable of reversing model replication forks plasmids used in this study and primers used for construc- in vitro (25,26). Additionally, both proteins physically inter- tion and validation are listed in Supplementary Tables S7 act with a Rad6-Rad18 counterpart and cooperate with an and 8. Mms2-Ubc13 E2 ubiquitin ligase heterodimer to mediate Lys-63-linked PCNA polyubiquitination (12,27,28). Genet- ically, HLTF is capable of partially complementing rad5Δ in Cancer genomics ultraviolet radiation (UV)-treated yeast, albeit in a transle- Copy number and mRNA expression data for primary tu- sion synthesis deficient background28 ( ). mor samples originate from The Cancer Genome Atlas The RAD5 gene was initially discovered on the basis of (https://cancergenome.nih.gov). These data were accessed UV sensitivity, and reduced forward mutation rates in for- via the Memorial Sloan Kettering computational biology ward genetic screens performed in the late 1960s and early portal R package (http://www.cbioportal.org) which pro- 1970s and much progress has been made since in elucidat- vides access to TCGA data processed using the Broad in- ing its roles in PRR (29–32). While it is clear that Rad5 stitute GDAC firehose pipeline (https://gdac.broadinstitute. contributes to regulating PRR through PCNA modifica- org)(15,36,37). Gene level threshold GISTIC scores were tion, the mechanism of PCNA polyubiquitination in pro- used to classify the predicted ploidy of genes in a given tu- moting template switching is unclear. Furthermore, while mor sample with a score of 2 representing
Recommended publications
  • UBE2N Antibody (N-Term) Blocking Peptide Synthetic Peptide Catalog # Bp13846a
    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 UBE2N Antibody (N-term) Blocking peptide Synthetic peptide Catalog # BP13846a Specification UBE2N Antibody (N-term) Blocking UBE2N Antibody (N-term) Blocking peptide - peptide - Background Product Information The modification of proteins with ubiquitin is Primary Accession P61088 animportant cellular mechanism for targeting abnormal or short-livedproteins for degradation. Ubiquitination involves at least UBE2N Antibody (N-term) Blocking peptide - Additional Information threeclasses of enzymes: ubiquitin-activating enzymes, or E1s,ubiquitin-conjugating enzymes, or E2s, and ubiquitin-proteinligases, Gene ID 7334 or E3s. This gene encodes a member of the E2ubiquitin-conjugating enzyme family. Other Names Studies in mouse suggest thatthis protein plays Ubiquitin-conjugating enzyme E2 N, a role in DNA postreplication repair. Bendless-like ubiquitin-conjugating enzyme, [providedby RefSeq]. Ubc13, UbcH13, Ubiquitin carrier protein N, Ubiquitin-protein ligase N, UBE2N, BLU UBE2N Antibody (N-term) Blocking Target/Specificity peptide - References The synthetic peptide sequence used to generate the antibody AP13846a was Zhao, J., et al. BMC Med. Genet. 11, 96 (2010) selected from the N-term region of UBE2N. :Markson, G., et al. Genome Res. A 10 to 100 fold molar excess to antibody is 19(10):1905-1911(2009)Topisirovic, I., et al. recommended. Precise conditions should be Proc. Natl. Acad. Sci. U.S.A. optimized for a particular assay. 106(31):12676-12681(2009)Yin, Q., et al. Nat. Struct. Mol. Biol. 16(6):658-666(2009)van Wijk, Format S.J., et al. Mol. Syst. Biol. 5, 295 (2009) : Peptides are lyophilized in a solid powder format.
    [Show full text]
  • Ubiquitin and Ubiquitin-Like Proteins Are Essential Regulators of DNA Damage Bypass
    cancers Review Ubiquitin and Ubiquitin-Like Proteins Are Essential Regulators of DNA Damage Bypass Nicole A. Wilkinson y, Katherine S. Mnuskin y, Nicholas W. Ashton * and Roger Woodgate * Laboratory of Genomic Integrity, National Institute of Child Health and Human Development, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, USA; [email protected] (N.A.W.); [email protected] (K.S.M.) * Correspondence: [email protected] (N.W.A.); [email protected] (R.W.); Tel.: +1-301-435-1115 (N.W.A.); +1-301-435-0740 (R.W.) Co-first authors. y Received: 29 August 2020; Accepted: 29 September 2020; Published: 2 October 2020 Simple Summary: Ubiquitin and ubiquitin-like proteins are conjugated to many other proteins within the cell, to regulate their stability, localization, and activity. These modifications are essential for normal cellular function and the disruption of these processes contributes to numerous cancer types. In this review, we discuss how ubiquitin and ubiquitin-like proteins regulate the specialized replication pathways of DNA damage bypass, as well as how the disruption of these processes can contribute to cancer development. We also discuss how cancer cell survival relies on DNA damage bypass, and how targeting the regulation of these pathways by ubiquitin and ubiquitin-like proteins might be an effective strategy in anti-cancer therapies. Abstract: Many endogenous and exogenous factors can induce genomic instability in human cells, in the form of DNA damage and mutations, that predispose them to cancer development. Normal cells rely on DNA damage bypass pathways such as translesion synthesis (TLS) and template switching (TS) to replicate past lesions that might otherwise result in prolonged replication stress and lethal double-strand breaks (DSBs).
    [Show full text]
  • Identification and Characterisation of Human Cytomegalovirus-Mediated Degradation of Helicase-Like Transcription Factor
    Identification and Characterisation of Human Cytomegalovirus-Mediated Degradation of Helicase-Like Transcription Factor Kai-Min Lin Department of Medicine Cambridge Institute for Medical Research University of Cambridge This dissertation is submitted for the degree of Doctor of Philosophy Fitzwilliam College September 2020 Declaration I hereby declare, that except where specific reference is made to the work of others, the contents of this dissertation are original and have not been submitted in whole or in part for consideration for any other degree of qualification in this, or any other university. This dissertation is the result of my own work and includes nothing which is the outcome of work done in collaboration except as where specified in the text and acknowledgments. This dissertation does not exceed the specified word limit of 60,000 words as defined by the Degree Committee, excluding figures, photographs, tables, appendices and bibliography. Kai-Min Lin September, 2020 I Summary Identification and characterisation of human cytomegalovirus-mediated degradation of helicase-like transcription factor Kai-Min Lin Viruses are known to degrade host factors that are important in innate antiviral immunity in order to infect successfully. To systematically identify host proteins targeted for early degradation by human cytomegalovirus (HCMV), the lab developed orthogonal screens using high resolution multiplexed mass spectrometry. Taking advantage of broad and selective proteasome and lysosome inhibitors, proteasomal degradation was found to be heavily exploited by HCMV. Several known antiviral restriction factors, including components of cellular promyelocytic leukemia (PML) were enriched in a shortlist of proteasomally degraded proteins during infection. A particularly robust novel ‘hit’ was helicase-like transcription factor (HLTF), a DNA repair protein that participates in error-free repair of stalled replication forks.
    [Show full text]
  • Loss of HLTF Function Promotes Intestinal Carcinogenesis Sumit Sandhu1, Xiaoli Wu1, Zinnatun Nabi1, Mojgan Rastegar1,3,4, Sam Kung3, Sabine Mai1,2 and Hao Ding1*
    Sandhu et al. Molecular Cancer 2012, 11:18 http://www.molecular-cancer.com/content/11/1/18 RESEARCH Open Access Loss of HLTF function promotes intestinal carcinogenesis Sumit Sandhu1, Xiaoli Wu1, Zinnatun Nabi1, Mojgan Rastegar1,3,4, Sam Kung3, Sabine Mai1,2 and Hao Ding1* Abstract Background: HLTF (Helicase-like Transcription Factor) is a DNA helicase protein homologous to the SWI/SNF family involved in the maintenance of genomic stability and the regulation of gene expression. HLTF has also been found to be frequently inactivated by promoter hypermethylation in human colon cancers. Whether this epigenetic event is required for intestinal carcinogenesis is unknown. Results: To address the role of loss of HLTF function in the development of intestinal cancer, we generated Hltf deficient mice. These mutant mice showed normal development, and did not develop intestinal tumors, indicating that loss of Hltf function by itself is insufficient to induce the formation of intestinal cancer. On the Apcmin/+ mutant background, Hltf- deficiency was found to significantly increase the formation of intestinal adenocarcinoma and colon cancers. Cytogenetic analysis of colon tumor cells from Hltf -/-/Apcmin/+ mice revealed a high incidence of gross chromosomal instabilities, including Robertsonian fusions, chromosomal fragments and aneuploidy. None of these genetic alterations were observed in the colon tumor cells derived from Apcmin/+ mice. Increased tumor growth and genomic instability was also demonstrated in HCT116 human colon cancer cells in which HLTF expression was significantly decreased. Conclusion: Taken together, our results demonstrate that loss of HLTF function promotes the malignant transformation of intestinal or colonic adenomas to carcinomas by inducing genomic instability.
    [Show full text]
  • Lymph Node Metastasis Is Infrequent in Patients with Highly-Methylated Colorectal Cancer
    ANTICANCER RESEARCH 26: 55-58 (2006) Lymph Node Metastasis is Infrequent in Patients with Highly-methylated Colorectal Cancer KENJI HIBI1 and AKIMASA NAKAO2 1Department of Surgery, Seirei Hospital, 56 Kawanayama-machi, Showa-ku, Nagoya 466-8633; 2Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan Abstract. In this study, the combined methylation status of p16, was found to harbor promoter hypermethylation p16, p14, HLTF, CDH13 and RUNX3 was examined in 59 associated with the loss of protein expression in cancer cells resected primary colorectal cancers using methylation-specific (7). Though homozygous deletions of the p16 locus were not PCR and the methylation status was correlated with the present (8), p16 promoter methylation was detected in clinicopathological features of the affected patients. A colorectal cancer (9). Subsequently, it has been found that significant difference was found in lymph node metastasis human p14 was also silenced by promoter hypermethylation (p=0.0359) on comparing the methylation status in in colorectal cancer (10). p14 interacts with the MDM2 colorectal cancers with lymph node metastasis to those protein and neutralizes the MDM2-mediated degradation without. There was also a significant gender difference of p53. Thus, p14 acts as a tumor suppressor gene via (p=0.0248) when the methylation status was compared. inhibition of p53 degradation. These studies indicated that Colorectal cancer without lymph node metastasis frequently p16 and p14 inactivation due to promoter methylation was exhibited aberrant methylation of the p16, p14, HLTF, important for colorectal tumorigenesis. We previously CDH13 and RUNX3 genes. examined the methylation status of these genes in 86 primary colorectal cancers using methylation-specific PCR There is now strong evidence that a series of genetic (MSP) (11).
    [Show full text]
  • Fission Yeast Rad8/HLTF Facilitates Rad52-Dependent Chromosomal
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.05.425428; this version posted January 6, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Fission yeast Rad8/HLTF facilitates Rad52-dependent 2 chromosomal rearrangements through PCNA lysine 107 3 ubiquitination 4 5 Jie Su, Naoko Toyofuku, Takuro Nakagawa * 6 Department of Biological Sciences, Graduate School of Science, Osaka University, Japan 7 *For correspondence: [email protected] 8 9 10 Abstract 11 Rad52 recombinase can cause gross chromosomal rearrangements (GCRs). However, the 12 mechanism of Rad52-dependent GCRs remains unclear. Here, we show that fission yeast 13 Rad8/HLTF facilitates Rad52-dependent GCRs through the ubiquitination of lysine 107 (K107) 14 of PCNA, a DNA sliding clamp. Loss of Rad8 reduced isochromosomes resulting from 15 centromere inverted repeat recombination. Rad8 HIRAN and RING finger mutations reduced 16 GCRs, suggesting that Rad8 facilitates GCRs through 3' DNA-end binding and ubiquitin ligase 17 activity. Mms2 and Ubc4 but not Ubc13 ubiquitin-conjugating proteins were required for GCRs. 18 Consistent with this, PCNA K107R but not K164R mutation greatly reduced GCRs. Rad8- 19 dependent PCNA K107 ubiquitination facilitates Rad52-dependent GCRs, as PCNA K107R, 20 rad8, and rad52 mutations epistatically reduced GCRs. Remarkably, K107 is located at the 21 interface between PCNA subunits, and an interface mutation D150E bypassed the requirement 22 of PCNA K107 ubiquitination for GCRs.
    [Show full text]
  • UBE2N Antibody Order 021-34695924 [email protected] Support 400-6123-828 50Ul [email protected] 100 Ul √ √ Web
    TD8193 UBE2N Antibody Order 021-34695924 [email protected] Support 400-6123-828 50ul [email protected] 100 uL √ √ Web www.ab-mart.com.cn Description: The UBE2V1-UBE2N and UBE2V2-UBE2N heterodimers catalyze the synthesis of non- canonical 'Lys-63'-linked polyubiquitin chains. This type of polyubiquitination does not lead to protein degradation by the proteasome. Mediates transcriptional activation of target genes. Plays a role in the control of progress through the cell cycle and differentiation. Plays a role in the error-free DNA repair pathway and contributes to the survival of cells after DNA damage. Acts together with the E3 ligases, HLTF and SHPRH, in the 'Lys-63'- linked poly-ubiquitination of PCNA upon genotoxic stress, which is required for DNA repair. Appears to act together with E3 ligase RNF5 in the 'Lys-63'-linked polyubiquitination of JKAMP thereby regulating JKAMP function by decreasing its association with components of the proteasome and ERAD. Promotes TRIM5 capsid-specific restriction activity and the UBE2V1-UBE2N heterodimer acts in concert with TRIM5 to generate 'Lys-63'-linked polyubiquitin chains which activate the MAP3K7/TAK1 complex which in turn results in the induction and expression of NF-kappa-B and MAPK-responsive inflammatory genes. Together with RNF135 and UB2V1, catalyzes the viral RNA-dependent 'Lys-63'-linked polyubiquitination of RIG-I/DDX58 to activate the downstream signaling pathway that leads to interferon beta production. Uniprot:P61088 Alternative Names: Bendless like ubiquitin conjugating enzyme;
    [Show full text]
  • Highly-Methylated Colorectal Cancers Show Poorly-Differentiated Phenotype
    ANTICANCER RESEARCH 26: 4263-4266 (2006) Highly-methylated Colorectal Cancers Show Poorly-differentiated Phenotype KENJI HIBI1,2 and AKIMASA NAKAO2 1Department of Surgery, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama 227-8501; 2Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8560, Japan Abstract. The combined methylation status of p16, p14, HLTF, human p14 was also silenced by promoter hypermethylation SOCS-1, CDH13, RUNX3 and CHFR was examined in 58 in colorectal cancer (10). p14 interacts with the MDM2 resected primary colorectal cancers using methylation-specific protein and neutralizes the MDM2-mediated degradation of PCR, and the methylation status was correlated with the p53. Thus, p14 acts as a tumor suppressor gene via inhibition clinicopathological features of the affected patients. A significant of p53 degradation. These studies indicated that p16 and p14 difference in histology (p=0.0041) was observed when the number inactivation due to promoter methylation was important for of methylated genes of poorly-differentiated colorectal cancers was colorectal tumorigenesis. We previously examined the compared to that of other differentiated ones. Poorly-differentiated methylation status of these genes in 86 primary colorectal colorectal cancers preferentially exhibited gene methylation. cancers using methylation-specific PCR (MSP) (11). Aberrant promoter methylation of p16 and p14 genes was detected in There is now strong evidence that a series of genetic 43 out of 86 (50 %) and 25 out of 86 (29%) colorectal cancer alterations in both dominant oncogenes and tumor suppressor specimens, respectively. genes are involved in the pathogenesis of human colorectal The loss of expression of a helicase-like transcription factor cancer.
    [Show full text]
  • Temporal Epigenomic Profiling Identifies AHR As a Dynamic Super-Enhancer Controlled Regulator of Mesenchymal Multipotency
    bioRxiv preprint doi: https://doi.org/10.1101/183988; this version posted November 17, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Gerard et al.: Time-series epigenomic profiles of mesenchymal differentiation 1 Temporal epigenomic profiling identifies AHR as a 2 dynamic super-enhancer controlled regulator of 3 mesenchymal multipotency 4 Deborah Gérard1, Florian Schmidt2,3, Aurélien Ginolhac1, Martine Schmitz1, 5 Rashi Halder4, Peter Ebert3, Marcel H. Schulz2,3, Thomas Sauter1 and Lasse 6 Sinkkonen1* 7 1Life Sciences Research Unit, University of Luxembourg, L-4367 Belvaux, 8 Luxembourg 9 2Excellence Cluster for Multimodal Computing and Interaction, Saarland Informatics 10 Campus, Germany 11 3Computational Biology & Applied Algorithmics, Max Planck Institute for 12 Informatics, Saarland Informatics Campus, Germany 13 4Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur- 14 Alzette, L-4362, Luxembourg 15 16 [email protected]; [email protected]; [email protected]; 17 [email protected]; [email protected]; [email protected]; 18 [email protected]; [email protected]; [email protected] 19 20 *Corresponding author: Dr. Lasse Sinkkonen 21 Life Sciences Research Unit, University of Luxembourg 22 6, Avenue du Swing, L-4367 Belvaux, Luxembourg 23 Tel.: +352-4666446839 24 E-mail: [email protected] 25 1 bioRxiv preprint doi: https://doi.org/10.1101/183988; this version posted November 17, 2017.
    [Show full text]
  • The Role of SMARCAD1 During Replication Stress Sarah Joseph
    The role of SMARCAD1 during replication stress Sarah Joseph Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2020 © 2020 Sarah Joseph All Rights Reserved Abstract The role of SMARCAD1 during replication stress Sarah Joseph Heterozygous mutations in BRCA1 or BRCA2 predispose carriers to an increased risk for breast or ovarian cancer. Both BRCA1 and BRCA2 (BRCA1/2) play an integral role in promoting genomic stability through their respective actions during homologous recombination (HR) mediated repair and stalled replication fork protection from nucleolytic degradation. SMARCAD1 (SD1) is a SWI/SNF chromatin remodeler that has been implicated in promoting long-range end resection and contributes to HR. Using human cell lines, we show that SMARCAD1 promotes nucleolytic degradation in BRCA1/2-deficient cells dependent on its chromatin remodeling activity. Moreover, SMARCAD1 prevents DNA break formation and promotes fork restart at stalled replication forks. These studies identify a new role for SMARCAD1 at the replication fork. In addition to the work presented here, I discuss a method for introducing stop codons (nonsense mutations) into genes using CRISPR-mediated base editing, called iSTOP, and provide an online resource for accessing the sequence of iSTOP sgRNASs (sgSTOPs) for five base editor variants (VQR-BE3, EQR-BE3, VRER-BE3, SaBE3, and SaKKH-BE3) in humans and over 3 million targetable gene coordinates for eight eukaryotic species. Ultimately, with improvements to CRISPR base editors this method can help model and study nonsense mutations in human disease. Table of Contents List of Figures .................................................................................................................
    [Show full text]
  • Gene Section Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL INIST-CNRS Gene Section Review HLTF (helicase-like transcription factor) Ludovic Dhont, Alexandra Belayew Molecular Biology, Health Institute, University of Mons, Mons, Belgium. [email protected] Published in Atlas Database: November 2016 Online updated version : http://AtlasGeneticsOncology.org/Genes/HLTFID42332ch3q24.html Printable original version : http://documents.irevues.inist.fr/bitstream/handle/2042/68527/11-2016-HLTFID42332ch3q24.pdf DOI: 10.4267/2042/68527 This article is an update of : HLTF (helicase-like transcription factor). Atlas Genet Cytogenet Oncol Haematol Dimitrova J, Belayew A. HLTF (helicase-like transcription factor). Atlas Genet Cytogenet Oncol Haematol 2010;14(10) This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2017 Atlas of Genetics and Cytogenetics in Oncology and Haematology Abstract domains involved in DNA repair. HLTF is a transcription factor - The Helicase-Like These data support a role of tumor suppressor gene Transcription Factor (HLTF/SMARCA3) belongs to for HLTF. the family of SWI/SNF proteins that use the energy The first association between HLTF inactivation and of ATP hydrolysis to remodel chromatin in a variety tumorigenesis was shown when hypermethylation of of cellular processes. the HLTF promoter was detected in 43% of primary Several groups independently isolated HLTF colon tumors and 22-55% of gastric cancers. through its capacity to selectively interact with a Moreover, HLTF deficiency in Apc-/+ mice induced DNA cis-element in the promoter or enhancer of the transition from colon adenocarcinoma to a different genes involved in cardiac development carcinoma with high chromosomal instability.
    [Show full text]
  • Methylation of Serum DNA Is an Independent Prognostic Marker In
    Imaging, Diagnosis, Prognosis Methylation of Serum DNA Is an Independent Prognostic Marker in Colorectal Cancer Maike Wallner,1Andreas Herbst,1Andrea Behrens,1Alexander Crispin,2 Petra Stieber,3 Burkhard Go« ke,1RolfLamerz, 1and Frank T. Kolligs1 Abstract Purpose: Aberrant CpG island hypermethylation is a feature of a subgroup of colorectal cancers, which can be detected in the serum ofaffected patients. This study was designed to identify methylation targets with prognostic significance in the serum of patients with colorectal cancer. Experimental Design: In a gene evaluation set consisting ofsera from 24 patients with local colorectal cancers, 14 with metastasized disease, and 20 healthy controls, the genes HPP1/TPEF, HLTF,andhMLH1were identified as potential serum DNA methylation markers.These genes were further analyzed in a test set of sera of 104 patients with colorectal cancer. Results: Methylation of HLTF, HPP1/TPEF,andhMLH1 was found to be significantly correlated with tumor size, and methylation of HLTF and HPP1/TPEF was significantly associated with metastatic disease and tumor stage. Moreover, methylation of HPP1/TPEF was also associated with serum carcinoembryonic antigen. The prognostic relevance ofmethylation ofthese genes was tested in pretherapeutic sera of77 patients with known follow-up. Patients with methylation of HPP1/TPEF or HLTF were found to have unfavorable prognosis (P = 0.001 and 0.008). In contrast, serum methylation of hMLH1was not associated with a higher risk ofdeath. Multivariate analysis showed methylated HPP1 and/or HLTF serum DNA to be independently associated with poor outcome and a relative risk ofdeath of3.4 (95% confidence interval, 1.4-8.1; P = 0.007).
    [Show full text]